摘要
目的探析在无痛人流手术中选择舒芬太尼联合丙泊酚的临床麻醉效果。方法探析样本为2016年1—12月间在该医院当中进行无痛人流手术患者中方便选择出48例。以计算机表法完成各组处理、分配,参照组(n=24)选择丙泊酚进行单一麻醉,研究组(n=24)选择舒芬太尼+丙泊酚进行联合麻醉。然后,观察患者们对麻醉的满意度、VAS评分参数、生命体征等多个指标。结果研究组麻醉满意度95.83%、参照组66.67%(χ~2=6.700 9,P=0.009 6);研究组VAS评分(3.04±1.01)分、参照组(3.92±1.63)分(t=2.248 2,P=0.029 4);生命体征上,研究组MAP(92.2±6.2)mmHg、参照组(98.0±5.6)mmHg(t=3.400 9,P=0.001 4),研究组HR(69.5±6.3)次/min、参照组(65.7±6.1)次/min(t=2.122 8,P=0.039 2),研究组SpO2(99.1±0.5)%、参照组SpO2(94.7±1.1)%(t=17.839 4,P=0.000 0)。结论患者进行无痛人流手术中,规范选择舒芬太尼+丙泊酚进行联合麻醉,作用效果好,且能够获得很高的麻醉满意度,推广意义重大。
Objective To analyze the clinical anesthetic effect of sufentanil combined with propofol in painless abortion. Methods A total of 48 patients were convenient selected for painless abortion in the hospital. The time was controlled from January to December 2016. The treatment and distribution of each group were performed by computer table method. Propo- fol was selected for single anesthesia in the reference group (n=24), and the study group (n=24) was treated with sufentanil propofol for combined anesthesia. Then, observe the patient's satisfaction with anesthesia, VAS score parameters, vital signs and other indicators. Results The anesthesia satisfaction of the study group was 95.83%, the reference group was 66.67% (X2=6.700 9, P=0.009 6); the VAS score of the study group was (3.04±1.01)points and the reference group (3.92± 1.63)points (t=2.248 2, P=0.029 4); On the vital signs, the study group MAP (92.2±6.2) mmHg, the reference group (98.0_± 5.6) mmHg (t=3.400 9, P=0.001 4), the study group HR (69.5_±6.3)times/min, the reference group (65.7±6.1)times/min (t= 2.122 8, P=0.039 2), study group SPO2(99.1±0.5)%, reference group SpO2 (94.7±1.1)% (t=17.839 4, P=0.000 0). Conclusion In patients with painless abortion, the combination of sufentanil + propofol is recommended for combined anesthesia, and the effect is good, and high anesthesia satisfaction can be obtained.
作者
董维秀
DONG Wei-xiu(Department of Maternal and Child Health,Nanping Maternal and Child Health Hospital,Nanping,Fujian Province,353000 China)
出处
《中外医疗》
2018年第31期112-114,共3页
China & Foreign Medical Treatment